IBDEI08E ; ; 20-FEB-2013
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 20, 2013
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,11075,2)
 ;;=^267279
 ;;^UTILITY(U,$J,358.3,11076,0)
 ;;=171.9^^91^746^50
 ;;^UTILITY(U,$J,358.3,11076,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11076,1,1,0)
 ;;=1^171.9
 ;;^UTILITY(U,$J,358.3,11076,1,2,0)
 ;;=2^SARCOMAS/OTH SOFT TISSUE CANCER
 ;;^UTILITY(U,$J,358.3,11076,2)
 ;;=^267165
 ;;^UTILITY(U,$J,358.3,11077,0)
 ;;=150.9^^91^746^16
 ;;^UTILITY(U,$J,358.3,11077,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11077,1,1,0)
 ;;=1^150.9
 ;;^UTILITY(U,$J,358.3,11077,1,2,0)
 ;;=2^ESOPHAGEAL CANCER
 ;;^UTILITY(U,$J,358.3,11077,2)
 ;;=^267055
 ;;^UTILITY(U,$J,358.3,11078,0)
 ;;=153.9^^91^746^15
 ;;^UTILITY(U,$J,358.3,11078,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11078,1,1,0)
 ;;=1^153.9
 ;;^UTILITY(U,$J,358.3,11078,1,2,0)
 ;;=2^COLON CANCER
 ;;^UTILITY(U,$J,358.3,11078,2)
 ;;=^267078
 ;;^UTILITY(U,$J,358.3,11079,0)
 ;;=152.9^^91^746^55
 ;;^UTILITY(U,$J,358.3,11079,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11079,1,1,0)
 ;;=1^152.9
 ;;^UTILITY(U,$J,358.3,11079,1,2,0)
 ;;=2^SMALL INTESTINE CANCER
 ;;^UTILITY(U,$J,358.3,11079,2)
 ;;=^267077
 ;;^UTILITY(U,$J,358.3,11080,0)
 ;;=193.^^91^746^60
 ;;^UTILITY(U,$J,358.3,11080,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11080,1,1,0)
 ;;=1^193.
 ;;^UTILITY(U,$J,358.3,11080,1,2,0)
 ;;=2^THYROID CANCER
 ;;^UTILITY(U,$J,358.3,11080,2)
 ;;=^267296
 ;;^UTILITY(U,$J,358.3,11081,0)
 ;;=284.9^^91^746^3
 ;;^UTILITY(U,$J,358.3,11081,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11081,1,1,0)
 ;;=1^284.9
 ;;^UTILITY(U,$J,358.3,11081,1,2,0)
 ;;=2^APLASTIC ANEMIA NOS
 ;;^UTILITY(U,$J,358.3,11081,2)
 ;;=^7020
 ;;^UTILITY(U,$J,358.3,11082,0)
 ;;=170.9^^91^746^6
 ;;^UTILITY(U,$J,358.3,11082,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11082,1,1,0)
 ;;=1^170.9
 ;;^UTILITY(U,$J,358.3,11082,1,2,0)
 ;;=2^BONE AND CARTILAGE CANCER
 ;;^UTILITY(U,$J,358.3,11082,2)
 ;;=^267155
 ;;^UTILITY(U,$J,358.3,11083,0)
 ;;=175.9^^91^746^9
 ;;^UTILITY(U,$J,358.3,11083,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11083,1,1,0)
 ;;=1^175.9
 ;;^UTILITY(U,$J,358.3,11083,1,2,0)
 ;;=2^BREAST CANCER-MALE
 ;;^UTILITY(U,$J,358.3,11083,2)
 ;;=^267205
 ;;^UTILITY(U,$J,358.3,11084,0)
 ;;=209.10^^91^746^10
 ;;^UTILITY(U,$J,358.3,11084,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11084,1,1,0)
 ;;=1^209.10
 ;;^UTILITY(U,$J,358.3,11084,1,2,0)
 ;;=2^CARCINOID, LARGE INTESTINE
 ;;^UTILITY(U,$J,358.3,11084,2)
 ;;=^336722
 ;;^UTILITY(U,$J,358.3,11085,0)
 ;;=209.29^^91^746^11
 ;;^UTILITY(U,$J,358.3,11085,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11085,1,1,0)
 ;;=1^209.29
 ;;^UTILITY(U,$J,358.3,11085,1,2,0)
 ;;=2^CARCINOID,NONBOWEL AND OTH SITE
 ;;^UTILITY(U,$J,358.3,11085,2)
 ;;=^336507
 ;;^UTILITY(U,$J,358.3,11086,0)
 ;;=209.00^^91^746^12
 ;;^UTILITY(U,$J,358.3,11086,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11086,1,1,0)
 ;;=1^209.00
 ;;^UTILITY(U,$J,358.3,11086,1,2,0)
 ;;=2^CARCINOID,SMALL INTESTINE
 ;;^UTILITY(U,$J,358.3,11086,2)
 ;;=^336721
 ;;^UTILITY(U,$J,358.3,11087,0)
 ;;=156.9^^91^746^13
 ;;^UTILITY(U,$J,358.3,11087,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11087,1,1,0)
 ;;=1^156.9
 ;;^UTILITY(U,$J,358.3,11087,1,2,0)
 ;;=2^CHOLANGIOCARCINOMA
 ;;^UTILITY(U,$J,358.3,11087,2)
 ;;=^267102
 ;;^UTILITY(U,$J,358.3,11088,0)
 ;;=286.9^^91^746^14
 ;;^UTILITY(U,$J,358.3,11088,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11088,1,1,0)
 ;;=1^286.9
 ;;^UTILITY(U,$J,358.3,11088,1,2,0)
 ;;=2^COAGULATION DEFECTS
 ;;^UTILITY(U,$J,358.3,11088,2)
 ;;=^87267
 ;;^UTILITY(U,$J,358.3,11089,0)
 ;;=156.9^^91^746^17
 ;;^UTILITY(U,$J,358.3,11089,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11089,1,1,0)
 ;;=1^156.9
 ;;^UTILITY(U,$J,358.3,11089,1,2,0)
 ;;=2^GALLBLADDER CANCER
 ;;^UTILITY(U,$J,358.3,11089,2)
 ;;=^267102
 ;;^UTILITY(U,$J,358.3,11090,0)
 ;;=459.0^^91^746^19
 ;;^UTILITY(U,$J,358.3,11090,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11090,1,1,0)
 ;;=1^459.0
 ;;^UTILITY(U,$J,358.3,11090,1,2,0)
 ;;=2^HEMORRHAGE NOS
 ;;^UTILITY(U,$J,358.3,11090,2)
 ;;=^55877
 ;;^UTILITY(U,$J,358.3,11091,0)
 ;;=176.9^^91^746^20
 ;;^UTILITY(U,$J,358.3,11091,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11091,1,1,0)
 ;;=1^176.9
 ;;^UTILITY(U,$J,358.3,11091,1,2,0)
 ;;=2^KAPOSI'S SARCOMA, NOS
 ;;^UTILITY(U,$J,358.3,11091,2)
 ;;=^107993
 ;;^UTILITY(U,$J,358.3,11092,0)
 ;;=161.9^^91^746^21
 ;;^UTILITY(U,$J,358.3,11092,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11092,1,1,0)
 ;;=1^161.9
 ;;^UTILITY(U,$J,358.3,11092,1,2,0)
 ;;=2^LARYNGEAL CANCER
 ;;^UTILITY(U,$J,358.3,11092,2)
 ;;=^267128
 ;;^UTILITY(U,$J,358.3,11093,0)
 ;;=208.90^^91^746^22
 ;;^UTILITY(U,$J,358.3,11093,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11093,1,1,0)
 ;;=1^208.90
 ;;^UTILITY(U,$J,358.3,11093,1,2,0)
 ;;=2^LEUKEMIA,UNSP CELL TYPE
 ;;^UTILITY(U,$J,358.3,11093,2)
 ;;=^336874
 ;;^UTILITY(U,$J,358.3,11094,0)
 ;;=140.9^^91^746^23
 ;;^UTILITY(U,$J,358.3,11094,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11094,1,1,0)
 ;;=1^140.9
 ;;^UTILITY(U,$J,358.3,11094,1,2,0)
 ;;=2^LIP CANCER
 ;;^UTILITY(U,$J,358.3,11094,2)
 ;;=^266994
 ;;^UTILITY(U,$J,358.3,11095,0)
 ;;=155.0^^91^746^24
 ;;^UTILITY(U,$J,358.3,11095,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11095,1,1,0)
 ;;=1^155.0
 ;;^UTILITY(U,$J,358.3,11095,1,2,0)
 ;;=2^LIVER CANCER
 ;;^UTILITY(U,$J,358.3,11095,2)
 ;;=^73526
 ;;^UTILITY(U,$J,358.3,11096,0)
 ;;=200.60^^91^746^26
 ;;^UTILITY(U,$J,358.3,11096,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11096,1,1,0)
 ;;=1^200.60
 ;;^UTILITY(U,$J,358.3,11096,1,2,0)
 ;;=2^LYMPHOMA,ANAPLASTIC LARGE CELL
 ;;^UTILITY(U,$J,358.3,11096,2)
 ;;=^335299
 ;;^UTILITY(U,$J,358.3,11097,0)
 ;;=200.20^^91^746^27
 ;;^UTILITY(U,$J,358.3,11097,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11097,1,1,0)
 ;;=1^200.20
 ;;^UTILITY(U,$J,358.3,11097,1,2,0)
 ;;=2^LYMPHOMA,BURKITT'S
 ;;^UTILITY(U,$J,358.3,11097,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,11098,0)
 ;;=201.90^^91^746^28
 ;;^UTILITY(U,$J,358.3,11098,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11098,1,1,0)
 ;;=1^201.90
 ;;^UTILITY(U,$J,358.3,11098,1,2,0)
 ;;=2^LYMPHOMA,HODGKIN'S
 ;;^UTILITY(U,$J,358.3,11098,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,11099,0)
 ;;=200.70^^91^746^29
 ;;^UTILITY(U,$J,358.3,11099,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11099,1,1,0)
 ;;=1^200.70
 ;;^UTILITY(U,$J,358.3,11099,1,2,0)
 ;;=2^LYMPHOMA,LARGE CELL
 ;;^UTILITY(U,$J,358.3,11099,2)
 ;;=^335300
 ;;^UTILITY(U,$J,358.3,11100,0)
 ;;=200.40^^91^746^30
 ;;^UTILITY(U,$J,358.3,11100,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11100,1,1,0)
 ;;=1^200.40
 ;;^UTILITY(U,$J,358.3,11100,1,2,0)
 ;;=2^LYMPHOMA,MANTLE CELL
 ;;^UTILITY(U,$J,358.3,11100,2)
 ;;=^335297
 ;;^UTILITY(U,$J,358.3,11101,0)
 ;;=200.30^^91^746^31
 ;;^UTILITY(U,$J,358.3,11101,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11101,1,1,0)
 ;;=1^200.30
 ;;^UTILITY(U,$J,358.3,11101,1,2,0)
 ;;=2^LYMPHOMA,MARGINAL ZONE
 ;;^UTILITY(U,$J,358.3,11101,2)
 ;;=^335296
 ;;^UTILITY(U,$J,358.3,11102,0)
 ;;=200.50^^91^746^33
 ;;^UTILITY(U,$J,358.3,11102,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11102,1,1,0)
 ;;=1^200.50
 ;;^UTILITY(U,$J,358.3,11102,1,2,0)
 ;;=2^LYMPHOMA,PRIM CTR NERVOUS SYS
 ;;^UTILITY(U,$J,358.3,11102,2)
 ;;=^335298
 ;;^UTILITY(U,$J,358.3,11103,0)
 ;;=202.90^^91^746^32
 ;;^UTILITY(U,$J,358.3,11103,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11103,1,1,0)
 ;;=1^202.90
 ;;^UTILITY(U,$J,358.3,11103,1,2,0)
 ;;=2^LYMPHOMA,OTHER SITE
 ;;^UTILITY(U,$J,358.3,11103,2)
 ;;=^267504
 ;;^UTILITY(U,$J,358.3,11104,0)
 ;;=200.10^^91^746^34
 ;;^UTILITY(U,$J,358.3,11104,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11104,1,1,0)
 ;;=1^200.10
 ;;^UTILITY(U,$J,358.3,11104,1,2,0)
 ;;=2^LYMPHOSARCOMA
 ;;^UTILITY(U,$J,358.3,11104,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,11105,0)
 ;;=172.9^^91^746^35
 ;;^UTILITY(U,$J,358.3,11105,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11105,1,1,0)
 ;;=1^172.9
 ;;^UTILITY(U,$J,358.3,11105,1,2,0)
 ;;=2^MALIGNANT MELANOMA
 ;;^UTILITY(U,$J,358.3,11105,2)
 ;;=^75462
 ;;^UTILITY(U,$J,358.3,11106,0)
 ;;=199.0^^91^746^37
 ;;^UTILITY(U,$J,358.3,11106,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11106,1,1,0)
 ;;=1^199.0
 ;;^UTILITY(U,$J,358.3,11106,1,2,0)
 ;;=2^METASTATIC CA OF UNKN PRIMARY
 ;;^UTILITY(U,$J,358.3,11106,2)
 ;;=^267340
 ;;^UTILITY(U,$J,358.3,11107,0)
 ;;=203.00^^91^746^38
 ;;^UTILITY(U,$J,358.3,11107,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11107,1,1,0)
 ;;=1^203.00
 ;;^UTILITY(U,$J,358.3,11107,1,2,0)
 ;;=2^MULTIPLE MYELOMA
 ;;^UTILITY(U,$J,358.3,11107,2)
 ;;=^336847
 ;;^UTILITY(U,$J,358.3,11108,0)
 ;;=238.75^^91^746^39
 ;;^UTILITY(U,$J,358.3,11108,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11108,1,1,0)
 ;;=1^238.75
 ;;^UTILITY(U,$J,358.3,11108,1,2,0)
 ;;=2^MYELODYSPLASTIC SYNDROME
 ;;^UTILITY(U,$J,358.3,11108,2)
 ;;=^334031
 ;;^UTILITY(U,$J,358.3,11109,0)
 ;;=157.9^^91^746^41
 ;;^UTILITY(U,$J,358.3,11109,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11109,1,1,0)
 ;;=1^157.9
 ;;^UTILITY(U,$J,358.3,11109,1,2,0)
 ;;=2^PANCREATIC CANCER
 ;;^UTILITY(U,$J,358.3,11109,2)
 ;;=^267103
 ;;^UTILITY(U,$J,358.3,11110,0)
 ;;=187.9^^91^746^42
 ;;^UTILITY(U,$J,358.3,11110,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11110,1,1,0)
 ;;=1^187.9
 ;;^UTILITY(U,$J,358.3,11110,1,2,0)
 ;;=2^PENILE CANCER
 ;;^UTILITY(U,$J,358.3,11110,2)
 ;;=^267252
 ;;^UTILITY(U,$J,358.3,11111,0)
 ;;=163.9^^91^746^44
 ;;^UTILITY(U,$J,358.3,11111,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11111,1,1,0)
 ;;=1^163.9
 ;;^UTILITY(U,$J,358.3,11111,1,2,0)
 ;;=2^PLEURAL CANCER
 ;;^UTILITY(U,$J,358.3,11111,2)
 ;;=^267140
 ;;^UTILITY(U,$J,358.3,11112,0)
 ;;=185.^^91^746^45
 ;;^UTILITY(U,$J,358.3,11112,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11112,1,1,0)
 ;;=1^185.
 ;;^UTILITY(U,$J,358.3,11112,1,2,0)
 ;;=2^PROSTATE CANCER
 ;;^UTILITY(U,$J,358.3,11112,2)
 ;;=^99481
 ;;^UTILITY(U,$J,358.3,11113,0)
 ;;=287.9^^91^746^46
 ;;^UTILITY(U,$J,358.3,11113,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11113,1,1,0)
 ;;=1^287.9
